ClinicalTrials.gg
CompletedNCT03381404MT-8554 MBUpdated Dec 17, 2025

Mass Balance Study With MT-8554

A Phase 1 interventional study of [14C] MT-8554 in Healthy Volunteer, sponsored by Tanabe Pharma America, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Study summary

This is a single-centre, open-label, mass balance study in healthy male subjects utilising a single oral dose of [14C] MT 8554.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Mass Balance Study with MT-8554
03

In context

Lead sponsor

Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Able to provide written to participate in this study after reading the participant information sheet and informed consent form and after having the opportunity to discuss the study with the Investigator or designee.
  • 2. Healthy and free from illness or disease as determined by medical history, physical examination, laboratory and other tests at Screening and Day 1.
  • 3. Male Caucasian subjects, aged 30 to 55 years (inclusive) at Screening.
  • 4. A body weight of ≥60 kg and a (Quetelet index) ranging from 18 to 30 kg/m2 (inclusive) at Screening or Day 1.
  • 5. Subjects and partners agree to use throughout the study as detailed in the Protocol body.
  • 6. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the Protocol restrictions and requirements.
  • 7. Regular daily bowel movements (i.e., production of at least one stool per day).

Exclusion criteria

Exclusion Criteria:

  • 1. Previously having received MT-8554.
  • 2. Participation in more than three clinical studies involving administration of an IMP in the previous year, or any study within 12 weeks (or, if relevant, five half-lives, whichever is the longer) prior to dosing.
  • 3. Presence or history of severe adverse reaction or allergy to any medicinal product that is of clinical significance.
  • 4. Subjects who have received any prescribed systemic or topical medication within 14 days (or, if relevant, five half-lives, whichever is longer) prior to dosing unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety. Subjects who have received slow release medicinal formulations considered to still be active within 14 days (or, if relevant, five half-lives, whichever is longer) prior to dosing will also be excluded unless, in the opinion of the Investigator or Sponsor, the medication will not interfere with the study procedures or compromise subject safety.
  • 5. Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days (or, if relevant, five half-lives, whichever is longer) prior to dosing unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety. Occasional use (2 g/day for 3 days) of paracetamol (acetaminophen) for mild analgesia is permitted.
  • 6. Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days (or, if relevant, five half-lives, whichever is longer) prior to dosing unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety.
  • 7. (in the opinion of the Investigator) endocrine, thyroid, hepatic (including Gilbert's syndrome), respiratory, gastrointestinal, renal, cardiovascular disease or history (within the last 2 years) of any significant psychiatric/psychotic illness disorder (including anxiety, depression and reactive depression).
  • 8. Clinically relevant abnormal medical history, physical findings or laboratory values at Screening or Day 1 that could interfere with the objectives of the study or compromise subject safety, as judged by the Investigator.
  • 9. Subjects with , alanine aminotransferase ≥1.5 × or total or creatine kinase above the reference range at Screening or Day 1.
  • 10. Subjects with \<60 mL/min (calculated using the Cockcroft-Gault-formula) at Screening.
  • 11. Family history of long or short syndrome, syncope of unknown cause or Torsades de Pointes.
  • 12. Clinically significant 12-lead (ECG) abnormalities, including subjects with corrected QT interval using Fridericia's formula (QTcF) of >450 ms, at Screening or Day 1, confirmed by repeat assessment.
  • 13. Blood pressure (supine) at Screening or Day 1 outside the range of 90 to 140 mmHg (systolic) or 50 to 90 mmHg (diastolic) and pulse rate outside the range of 40 to 100 beats per minute, confirmed by repeat assessment. Evidence of postural hypotension at Screening defined as a decrease of >20 mmHg in systolic or >10 mmHg in diastolic blood pressure between the supine and standing position, confirmed by repeat assessment.
  • 14. Tympanic body temperature at Day 1 that is outside the local reference range (35.5°C to 37.8°C), confirmed by repeat assessment.
  • 15. Excessive consumption of food or drink containing caffeine, including coffee, tea, cola, energy drinks or chocolates (≥5 cups of coffee or equivalent per day).
  • 16. Presence or history of drug abuse (as defined by [DSM-V] criteria) or a positive urine test for drugs of abuse at Screening or Day 1.
  • 17. Presence or history (in the last 2 years) of alcohol abuse, or intake of more than 28 units/224 g of alcohol weekly or a positive breath test for alcohol at Screening or Day 1. One unit/8 g is equivalent to a half-pint (280 mL) of beer or one measure (25 mL) of spirits or one glass (125 mL) of wine.
  • 18. Subjects who use tobacco or nicotine-containing products (cigarettes, snuff, chewing tobacco, cigars, pipes, e cigarettes or nicotine-replacement products) within 3 months prior to dosing, or positive urine cotinine test at Screening or Day 1.
  • 19. Test positive for surface antigen, hepatitis B core antibody, antibody or (HIV) 1 and HIV 2 antibodies at Screening.
  • 20. Donate one or more units of blood (450 mL) within 3 months prior to Screening, or plasma within 7 days prior to Screening, or within 6 weeks prior to Screening, or intention to donate blood within 3 months after the last scheduled visit.
  • 21. Consumption of food or drink containing red wine, Seville oranges (including marmalade), liquorice, cranberry (including fruit juice) or grapefruit (including fruit juice) from 7 days prior to Day 1.
  • 22. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, or which may jeopardise the subject in case of participation in the study. The Investigator should be guided by evidence of any of the following:
  • 23. History of irritable bowel syndrome, or other manifestation of abnormal bowel habit (e.g., diarrhoea, constipation);
  • 24. History of inflammatory bowel disease, gastritis, ulcers, gastrointestinal or rectal bleeding;
  • 25. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bowel resection;
  • 26. History or clinical evidence of pancreatic injury or pancreatitis.
  • 27. Radiation exposure, excluding background radiation but including that from the present study, diagnostic X-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C] MT-8554

    Drug: [14C] MT-8554

Interventions

06

What researchers measure

Primary outcomes

  1. Total radioactivity in urine and faeces

    Time frame: Up to 14 Days after dosing

  2. Maximum observed plasma concentration [Cmax]

    Time frame: Up to 14 Days after dosing

  3. Time at which Cmax occurs [tmax]

    Time frame: Up to 14 Days after dosing

  4. Area under the plasma concentration-time curve from time zero to the last measurable concentration [AUC0-last]

    Time frame: Up to 14 Days after dosing

  5. Apparent terminal elimination half-life [t1/2]

    Time frame: Up to 14 Days after dosing

  6. Terminal elimination rate constant [Kel]

    Time frame: Up to 14 Days after dosing

Secondary outcomes

  1. Safety and tolerability as measured by adverse events (AEs)

    Time frame: Up to 14 Days after dosing

  2. Safety and tolerability as measured by vital signs

    Time frame: Up to 14 Days after dosing

07

Study locations

1 site
  • Investigational center
    City Name, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jan 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 22, 2017
StartActual
Dec 19, 2017
Primary completionActual
Jan 29, 2018
CompletionActual
Jan 29, 2018
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03381404
Responsible party
Sponsor
First posted
Dec 22, 2017
Start date
Dec 19, 2017
Primary completion
Jan 29, 2018
Completion
Jan 29, 2018
Last update
Dec 17, 2025

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion